Abstract 3980
Background
RIB, an oral, selective CDK4/6 inhibitor, is approved for use in combination with endocrine therapy in women with HR+, HER2– ABC in the USA and EU. CompLEEment-1, an ongoing single-arm phase 3b trial, evaluated first-line RIB + LET with broad inclusion criteria to reflect a real-world HR+, HER2– ABC population. Here we report interim safety and efficacy in pts with VM or BOM.
Methods
Pts received RIB (600 mg/day, 3 weeks on/1 week off) + LET (2.5 mg/day). Men and premenopausal women also received goserelin (3.6 mg subcutaneously) or leuprolide (7.5 mg intramuscular injection) every 28 days. The primary outcome (safety) and key secondary outcomes (time to progression [TTP], overall response rate [ORR], and clinical benefit rate [CBR]) were reported for two subgroups: pts with VM and pts with BOM.
Results
Of the 3,246 pts, 1,983 (61.1%) had VM; among this group, 1,309 (66.0%) also had bone metastases. BOM were present in 706 pts (21.7%). At data cut-off (Aug 8, 2018), median duration of RIB exposure was 8.0 months in pts with VM and 8.8 months in pts with BOM. Median duration of study follow-up was 10.35 months. In pts with VM, the most common adverse events were neutropenia (57.2%), nausea (35.2%), and fatigue (22.5%); 12.5% discontinued due to AEs. Estimated 12-month event-free probability (EFP) in pts with VM was 63.1% (95% confidence interval [CI], 59.5-66.6%), ORR was 30.7% (95% CI, 28.4-33.1%) and CBR was 62.8% (95% CI, 60.3-65.2%). In pts with BOM, the most common AEs were neutropenia (57.8%), nausea (33.3%), and fatigue (21.5%); 11.8% discontinued due to AEs. The estimated 12-month EFP in the BOM subgroup was 82.8% (95% CI, 78.6-86.3%), ORR was 20.6% (95% CI, 14.8-27.3%), and CBR was 69.1% (95% CI, 61.7-75.9%).
Conclusions
Safety and efficacy outcomes in this post hoc analysis support the use of RIB + LET in pts with VM and BOM. Pts with BOM were less likely to have an objective tumor response but more likely to be progression free at 12 months, consistent with the more favorable prognosis of BOM compared with non-osseous metastases.
Clinical trial identification
NCT02941926.
Editorial acknowledgement
Medical editorial assistance was provided by Joe Hodgson of Healthcare Consultancy Group, LLC, and funded by Novartis Pharmaceuticals Corporation.
Legal entity responsible for the study
Novartis.
Funding
Novartis Pharmaceuticals.
Disclosure
M. De Laurentiis: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Celgene; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: AstraZeneca; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Eisai; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Eli Lilly; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Amgen. A. Ring: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer. M. Campone: Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Eli Lilly; Honoraria (institution), Advisory / Consultancy: Sanofi; Honoraria (institution), Advisory / Consultancy: Servier; Honoraria (institution), Advisory / Consultancy: Accord; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Abbvie. T. Bachelot: Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer. W. Jacot: Honoraria (self): Pierre Fabre; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Research grant / Funding (institution): AstraZeneca. P. Marchetti: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Incyte; Advisory / Consultancy, Speaker Bureau / Expert testimony: Molteni; Advisory / Consultancy, Speaker Bureau / Expert testimony, Leadership role, Research grant / Funding (institution): Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Research grant / Funding (institution): Janssen. C. Timcheva: Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Servie. A. Gombos: Research grant / Funding (institution): Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract